Compare ASTRAZENECA PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALKEM LABORATORIES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALKEM LABORATORIES ASTRAZENECA PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 114.3 22.4 509.1% View Chart
P/BV x 35.0 5.4 646.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ASTRAZENECA PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ALKEM LABORATORIES
Mar-20
ASTRAZENECA PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2782,720 47.0%   
Low Rs8831,660 53.2%   
Sales per share (Unadj.) Rs228.4697.9 32.7%  
Earnings per share (Unadj.) Rs10.496.1 10.8%  
Cash flow per share (Unadj.) Rs16.3117.3 13.9%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs98.8515.2 19.2%  
Shares outstanding (eoy) m25.00119.57 20.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.1 150.7%   
Avg P/E ratio x104.222.8 457.5%  
P/CF ratio (eoy) x66.418.7 355.7%  
Price / Book Value ratio x10.94.3 257.3%  
Dividend payout %026.0 0.0%   
Avg Mkt Cap Rs m27,008261,879 10.3%   
No. of employees `0001.414.3 9.5%   
Total wages/salary Rs m1,53515,055 10.2%   
Avg. sales/employee Rs Th4,210.95,822.6 72.3%   
Avg. wages/employee Rs Th1,132.21,050.5 107.8%   
Avg. net profit/employee Rs Th191.1802.0 23.8%   
INCOME DATA
Net Sales Rs m5,71083,444 6.8%  
Other income Rs m1231,042 11.8%   
Total revenues Rs m5,83384,486 6.9%   
Gross profit Rs m46314,734 3.1%  
Depreciation Rs m1472,528 5.8%   
Interest Rs m0651 0.0%   
Profit before tax Rs m43812,598 3.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,105 16.2%   
Profit after tax Rs m25911,493 2.3%  
Gross profit margin %8.117.7 45.9%  
Effective tax rate %40.88.8 465.7%   
Net profit margin %4.513.8 32.9%  
BALANCE SHEET DATA
Current assets Rs m3,20954,960 5.8%   
Current liabilities Rs m2,07032,433 6.4%   
Net working cap to sales %20.027.0 73.9%  
Current ratio x1.61.7 91.5%  
Inventory Days Days7280 90.9%  
Debtors Days Days3572 48.4%  
Net fixed assets Rs m79032,710 2.4%   
Share capital Rs m50239 20.9%   
"Free" reserves Rs m2,41961,368 3.9%   
Net worth Rs m2,46961,607 4.0%   
Long term debt Rs m01,592 0.0%   
Total assets Rs m4,60599,433 4.6%  
Interest coverage xNM20.4-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 147.7%   
Return on assets %5.612.2 46.1%  
Return on equity %10.518.7 56.2%  
Return on capital %17.721.0 84.6%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m30016,061 1.9%   
Fx outflow Rs m2,0152,483 81.2%   
Net fx Rs m-1,71513,578 -12.6%   
CASH FLOW
From Operations Rs m885,851 1.5%  
From Investments Rs m-94-7,414 1.3%  
From Financial Activity Rs mNA792 0.0%  
Net Cashflow Rs m-6-731 0.8%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 33.1 0.9%  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 0.0 -  
Shareholders   12,856 68,381 18.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   J.B.CHEMICALS  SUVEN LIFE SCIENCES  WYETH  WOCKHARDT  VENUS REMEDIES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 16, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - CIPLA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS